Exercise Training Reduces Central Adiposity and Improves Metabolic Indices in HAART-treated HIV-positive Subjects in Rwanda: a Randomized Controlled Trial
Overview
Affiliations
As HAART becomes more accessible in sub-Saharan Africa, metabolic syndromes, body fat redistribution (BFR), and cardiovascular disease may become more prevalent. We conducted a 6-month, randomized controlled trial to test whether cardiorespiratory exercise training (CET), improves metabolic, body composition and cardiorespiratory fitness parameters in HAART-treated HIV(+) African subjects with BFR. Six months of CET reduced waist circumference (-7.13 +/- 4.4 cm, p < 0.0001), WHR (-0.10 +/- 0.1, p < 0.0001), sum skinfold thickness (-6.15 +/- 8.2 mm, p < 0.0001) and % body fat mass (-1.5 +/- 3.3, p < 0.0001) in HIV(+)BFR(+)EXS. Hip circumference was unchanged in non-exercise control groups. CET reduced fasting total cholesterol (-0.03 +/- 1.11 mM, p < 0.05), triglycerides (-0.22 +/-0.48 mM, p < 0.05) and glucose levels (-0.21 +/- 0.71 mM, p < 0.05) (p < 0.0001). HDL-, LDL-cholesterol and HOMA values were unchanged after CET. Interestingly, HIV(+) subjects randomized to non-exercising groups experienced increases in fasting plasma glucose levels, whereas HIV seronegative controls did not (p < 0.001). Predicted VO(2) peak increased more in the HIV(+)BFR(+)EXS than in all other groups (4.7 +/- 3.9 ml/kg/min, p < 0.0001). Exercise training positively modulated body composition and metabolic profiles, and improved cardiorespiratory fitness in HAART-treated HIV(+) Africans. These beneficial adaptations imply that exercise training is a safe, inexpensive, practical, and effective treatment for evolving metabolic and cardiovascular syndromes associated with HIV and HAART exposure in resource-limited sub-Saharan countries, where treatment is improving, morbidity and mortality rates are declining, but where minimal resources are available to manage HIVand HAART-associated cardiovascular and metabolic syndromes.
Nutritional and Lifestyle Therapy for NAFLD in People with HIV.
Cinque F, Cespiati A, Lombardi R, Guaraldi G, Sebastiani G Nutrients. 2023; 15(8).
PMID: 37111209 PMC: 10140991. DOI: 10.3390/nu15081990.
Mabweazara S, Manne-Goehler J, Hamer M, Cellini J, Siedner M Syst Rev. 2023; 12(1):24.
PMID: 36814348 PMC: 9948386. DOI: 10.1186/s13643-023-02186-5.
Kamkuemah M, Gausi B, Oni T, Middelkoop K PLoS One. 2023; 18(1):e0266637.
PMID: 36693111 PMC: 9873196. DOI: 10.1371/journal.pone.0266637.
Adedeji T, Adedeji N, Ajeigbe A, Smith O, Jeje O, Fawale M Curr HIV Res. 2022; 20(6):441-456.
PMID: 36056868 DOI: 10.2174/1570162X20666220901085926.
Lipidome Alterations with Exercise Among People With and Without HIV: An Exploratory Study.
Bowman E, Wilson M, Riedl K, MaWhinney S, Jankowski C, Funderburg N AIDS Res Hum Retroviruses. 2022; 38(7):544-551.
PMID: 35302400 PMC: 9297322. DOI: 10.1089/AID.2021.0154.